Home Newsfeeds Jefferies Maintains Buy on Provention Bio, Raises Price Target to $22

Jefferies Maintains Buy on Provention Bio, Raises Price Target to $22

Jefferies analyst Chris Howerton maintains Provention Bio (NASDAQ:PRVB) with a Buy and raises the price target from $18 to $22.

byBenzinga Newsdesk

November 18, 2022

1 minute read

Jefferies analyst Chris Howerton maintains Provention Bio (NASDAQ:PRVB) with a Buy and raises the price target from $18 to $22.

Amid Dogwifhat, Bonk Hype, Solana Co-Founder Isn’t Convinced Doing Good Redeems Bad Meme Coins: ‘Find This Logic To Be Nihilistic’

By Benzinga Neuro

March 31, 10:17 PM

Anatoly Yakovenko, the co-founder of Solana Labs, expressed his skepticism about the idea of meme coins contributing to public good.

$BONK

Analyst Ratings

Where Angi Stands With Analysts

By Benzinga Insights

November 9, 2:00 PM

Within the last quarter, Angi (NASDAQ:ANGI) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

ANGI

$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today

By Benzinga Insights

August 2, 10:18 AM

Lowe's Companies (NYSE:LOW) has outperformed the market over the past 20 years by 4.92% on an annualized basis producing an average annual return of 12.7%. Currently, Lowe's Companies has a market capitalization of $124.05 billion.

LOW

JP Morgan Maintains Overweight on Salesforce, Lowers Price Target to $200

By Benzinga Newsdesk

December 1, 9:24 AM

JP Morgan analyst Mark Murphy maintains Salesforce (NYSE:CRM) with a Overweight and lowers the price target from $245 to $200.

CRM

Jefferies Maintains Buy on Provention Bio, Raises Price Target to $22

Related Posts

Amid Dogwifhat, Bonk Hype, Solana Co-Founder Isn’t Convinced Doing Good Redeems Bad Meme Coins: ‘Find This Logic To Be Nihilistic’

Where Angi Stands With Analysts

$1000 Invested In This Stock 20 Years Ago Would Be Worth $11,000 Today

JP Morgan Maintains Overweight on Salesforce, Lowers Price Target to $200